Deltyba: new antibacterial for multidrug-resistant tuberculosis

Otsuka Novel Products has launched Deltyba (delamanid) for use as combination therapy for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adults where other agents cannot be used owing to resistance or intolerance.

 Deltyba (delamanid) should be given as directly observed therapy at a dose of 100mg (two tablets) twice daily with food for 6 months.
Deltyba (delamanid) should be given as directly observed therapy at a dose of 100mg (two tablets) twice daily with food for 6 months.

Delamanid is a nitro-dihydro-imidazooxazole derivative that inhibits mycolic acid synthesis and has potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.

A randomised, placebo-controlled trial in 481 patients with pulmonary multidrug-resistant tuberculosis showed that addition of delamanid 100mg twice daily to background therapy increased the sputum-culture conversion rate (as assessed in liquid broth medium) at 2 months to 45.4%, compared with 29.6% for addition of placebo (p=0.008). 

In an observational follow-up study in 421 participants, the rate of favourable outcomes (cure or treatment completion) at 24 months was significantly higher in those who received delamanid for ≥6 months than in those who were treated for ≤2 months (74.5% vs 55%; RR 1.35 [95% CI 1.17–1.56], p<0.001). Mortality rates were also significantly reduced with extended treatment (1.0% vs 8.3%, p<0.001). 

The most frequently reported adverse effects of delamanid were nausea, vomiting and dizziness. However, QT interval prolongation was the most notable safety concern.

The recommended dose for adults is 100mg twice daily for 24 weeks.

View Deltyba drug record

Further information: Otsuka Novel Products

Follow MIMS on Twitter

Sign up for MIMS bulletins

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more